Last reviewed · How we verify

QazCovid-in®-vaccine against COVID-19

Research Institute for Biological Safety Problems · Phase 3 active Biologic

QazCovid-in®-vaccine against COVID-19 is a Biologic drug developed by Research Institute for Biological Safety Problems. It is currently in Phase 3 development for Prevention of COVID-19 disease.

QazCovid-in stimulates an immune response to provide protection against COVID-19.

QazCovid-in stimulates an immune response to provide protection against COVID-19. Used for Prevention of COVID-19 disease.

At a glance

Generic nameQazCovid-in®-vaccine against COVID-19
SponsorResearch Institute for Biological Safety Problems
ModalityBiologic
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

QazCovid-in is a vaccine that works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body produce antibodies to fight the virus. This immune response provides protection against COVID-19.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about QazCovid-in®-vaccine against COVID-19

What is QazCovid-in®-vaccine against COVID-19?

QazCovid-in®-vaccine against COVID-19 is a Biologic drug developed by Research Institute for Biological Safety Problems, indicated for Prevention of COVID-19 disease.

How does QazCovid-in®-vaccine against COVID-19 work?

QazCovid-in stimulates an immune response to provide protection against COVID-19.

What is QazCovid-in®-vaccine against COVID-19 used for?

QazCovid-in®-vaccine against COVID-19 is indicated for Prevention of COVID-19 disease.

Who makes QazCovid-in®-vaccine against COVID-19?

QazCovid-in®-vaccine against COVID-19 is developed by Research Institute for Biological Safety Problems (see full Research Institute for Biological Safety Problems pipeline at /company/research-institute-for-biological-safety-problems).

What development phase is QazCovid-in®-vaccine against COVID-19 in?

QazCovid-in®-vaccine against COVID-19 is in Phase 3.

What are the side effects of QazCovid-in®-vaccine against COVID-19?

Common side effects of QazCovid-in®-vaccine against COVID-19 include Pain, redness, or swelling at the injection site, Fatigue, Headache.

Related